Clinical Trials Logo

Hyperoxaluria clinical trials

View clinical trials related to Hyperoxaluria.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT00280215 Withdrawn - Hyperoxaluria Clinical Trials

Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria

Start date: December 2007
Phase: Phase 3
Study type: Interventional

This study will test the effectiveness of two medications: ACEI (angiotensin converting enzyme inhibitor)and ARB (angiotensin receptor blocker) in reducing the renal injury induced by hyperoxaluria in patients with Primary Hyperoxaluria. Hypothesis: Calcium oxalate crystal deposition in the kidney causes inflammation and resulting injury to kidney tissue. Angiotensin blockade will improve these changes, thus slowing the progression of renal insufficiency in patients with Primary Hyperoxaluria.